Vantage Esmo 2021 roundup
Here's a roundup of Vantage's coverage of the 2021 European Society for Medical Oncology congress.
September 24
Esmo 2021 movers – a handful of biotech winners emerge
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
September 22
Astra lays out a grand vision for Enhertu
But proving that the drug’s toxicities are manageable in the real world will become more important as it moves into earlier treatment settings.
September 21
Beyondspring experiences winter of discontent
September 20
Astra coasts towards a new lung cancer combo
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
September 17
A move into the larger second-line breast cancer setting is surely on the way for the Astrazeneca and Daiichi drug.
Colorectal cancer could be Mirati’s golden ticket
Adagrasib looks better than Amgen’s Lumakras, which could explain why Mirati has been dragging its heels in lung cancer.
Opdivo’s glimmer of hope in front-line head and neck cancer
The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?
Keytruda challenges Jemperli and adjuvant melanoma
Glaxo’s anti-PD-1 MAb might not have a market niche to itself for long, while a separate trial could help Keytruda double its adjuvant melanoma potential.
Look out Agenus, Keytruda is about to put up a roadblock
Poziotinib could add first-line string to its bow
Mahogany loses its polish for Macrogenics
September 16
Astra finally sees a Wee1 signal
It might be too late for adavosertib, but others could benefit if a niche has finally been found for Wee1 inhibitors.
The jury remains out on CDK7 inhibition
Clinical data on Carrick’s samuraciclib and Syros’s SY-5609 show that this mechanism remains a work in progress.
September 13
Mirati bids to be belle of the ball (preview)
